Skip to main content
HR 1499 116th Congress House Health Administrative law and regulatory procedures Civil actions and liability Competition and antitrust Consumer affairs Drug safety, medical device, and laboratory regulation Federal Trade Commission (FTC) Intellectual property Judicial review and appeals Licensing and registrations Prescription drugs

Protecting Consumer Access to Generic Drugs Act of 2019

Introduced: March 5, 2019 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 11 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 10, 2019
Placed on the Union Calendar, Calendar No. 30.
May 10, 2019
Committee on the Judiciary discharged.
May 10, 2019
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-52, Part I.
Apr 8, 2019
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Apr 3, 2019
Ordered to be Reported (Amended) by Voice Vote.
Apr 3, 2019
Committee Consideration and Mark-up Session Held.
Mar 27, 2019
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
Mar 27, 2019
Subcommittee Consideration and Mark-up Session Held.
Mar 6, 2019
Referred to the Subcommittee on Health.
Mar 5, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Mar 5, 2019
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Protecting Consumer Access to Generic Drugs Act of 2019

This bill prohibits the manufacturer of a brand-name, generic, or biosimilar drug from entering into certain agreements to resolve or settle a patent infringement claim in connection with the sale of a drug or biological product.

Specifically, such an agreement shall, with some exceptions, be a violation of the bill if the filer of a subsequent application to market a drug or biological product receives anything of value and agrees to limit or forego research, development, manufacturing, marketing, or sales of the subsequent drug or biological product. (Typically, a subsequent application seeks to market a generic or biosimilar version of a patented drug or biological product.)

Penalties for violations of the bill include civil penalties and loss of the 180-day exclusivity period for a generic drug. The Federal Trade Commission (FTC) shall have exclusive authority to litigate to enforce the bill.

When a generic or biosimilar drug manufacturer enters into an agreement with another drug manufacturer related to the manufacturing, marketing or sale of a drug, the manufacturers must certify that the material they have given the FTC concerning the agreement contains (1) the complete agreement; and (2) any agreements related to the main agreement, including descriptions of any oral agreements or representations.

What's happening now May 10, 2019

Placed on the Union Calendar, Calendar No. 30.

 Related & companion bills 3
  • HR 19 Related bill Lower Costs, More Cures Act of 2019
  • HR 987 Related bill Strengthening Health Care and Lowering Prescription Drug Costs Act
  • HR 2700 Related bill Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act
 Bill text 2 versions

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
 Cosponsors 28
All 28 Democratic 27 Republican 1
D
Smith, Adam
Washington · May 9, 2019
 D
Underwood, Lauren
Illinois · May 9, 2019
 D
Carbajal, Salud O.
California · May 7, 2019
 D
Carson, André
Indiana · May 7, 2019
 D
Casten, Sean
Illinois · May 7, 2019
 D
Davids, Sharice
Kansas · May 7, 2019
 D
Houlahan, Chrissy
Pennsylvania · May 7, 2019
 D
Kelly, Robin L.
Illinois · May 7, 2019
 D
Cisneros, Gilbert Ray
California · May 1, 2019
 D
Stevens, Haley M.
Michigan · May 1, 2019
 D
Thompson, Bennie G.
Mississippi · May 1, 2019
 D
Raskin, Jamie
Maryland · Apr 29, 2019
 D
Quigley, Mike
Illinois · Apr 25, 2019
 D
Case, Ed
Hawaii · Apr 15, 2019
 D
Neguse, Joe
Colorado · Apr 15, 2019
 D
Larson, John B.
Connecticut · Apr 9, 2019
 D
Cohen, Steve
Tennessee · Apr 8, 2019
 D
Welch, Peter
Vermont · Apr 8, 2019
 D
Pappas, Chris
New Hampshire · Apr 4, 2019
 D
Schakowsky, Janice D.
Illinois · Apr 4, 2019
 D
Khanna, Ro
California · Apr 3, 2019
 D
Clarke, Yvette D.
New York · Apr 1, 2019
 R
Van Drew, Jefferson
New Jersey · Apr 1, 2019
 D
Matsui, Doris O.
California · Mar 27, 2019
 D
Craig, Angie
Minnesota · Mar 26, 2019
 D
Dingell, Debbie
Michigan · Mar 26, 2019
 D
Pallone, Frank
New Jersey · Mar 26, 2019
 D
Ruiz, Raul
California · Mar 26, 2019
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 1499: Protecting Consumer Access to Generic Drugs Act of 2019. 116th Congress. Open America. https://openamerica.io/bill/116-HR-1499/
MLA
"H.R. 1499: Protecting Consumer Access to Generic Drugs Act of 2019." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-1499/.
Bluebook (legal)
H.R. 1499, 116th Cong. (2026), https://openamerica.io/bill/116-HR-1499/.
Markdown link
[H.R. 1499: Protecting Consumer Access to Generic Drugs Act of 2019](https://openamerica.io/bill/116-HR-1499/)
Report a problem